During the last session, Cardiff Oncology Inc. (NASDAQ:CRDF)’s traded shares were 0.58 million, with the beta value of the company hitting 1.48. At the end of the trading day, the stock’s price was $2.53, reflecting an intraday gain of 4.55% or $0.11. The 52-week high for the CRDF share is $8.58, that puts it down -239.13 from that peak though still a striking 55.34% gain since the share price plummeted to a 52-week low of $1.13. The company’s market capitalization is $109.09M, and the average intraday trading volume over the past 10 days was 0.43 million shares, and the average trade volume was 960.00K shares over the past three months.
Cardiff Oncology Inc. (CRDF) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.70. CRDF has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 1 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.25.
Cardiff Oncology Inc. (NASDAQ:CRDF) trade information
Cardiff Oncology Inc. (CRDF) registered a 4.55% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 4.55% in intraday trading to $2.53 this Friday, 08/05/22, hitting a weekly high. The stock’s 5-day price performance is 14.48%, and it has moved by -18.91% in 30 days. Based on these gigs, the overall price performance for the year is -50.87%. The short interest in Cardiff Oncology Inc. (NASDAQ:CRDF) is 2.27 million shares and it means that shorts have 1.78 day(s) to cover.
The consensus price target of analysts on Wall Street is $12.67, which implies an increase of 80.03% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $7.00 and $22.00 respectively. As a result, CRDF is trading at a discount of -769.57% off the target high and -176.68% off the low.
Cardiff Oncology Inc. (CRDF) estimates and forecasts
Statistics show that Cardiff Oncology Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Cardiff Oncology Inc. (CRDF) shares have gone down -19.68% during the last six months, with a year-to-date growth rate less than the industry average at -42.47% against 1.00. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to shrink -47.10% this quarter and then drop -58.80% in the quarter after that. In the rating firms’ projections, revenue will decrease -24.80% compared to the previous financial year.
Revenue for the current quarter is expected to be $60k as predicted by 5 analyst(s). Meanwhile, a consensus of 5 analyst(s) estimates revenue growth to $60k by the end of Sep 2022.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 62.20%. While earnings are projected to return 33.00% in 2022.
Cardiff Oncology Inc. is due to release its next quarterly earnings between February 23 and February 28. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Cardiff Oncology Inc. (NASDAQ:CRDF)’s Major holders
Cardiff Oncology Inc. insiders own 7.12% of total outstanding shares while institutional holders control 39.10%, with the float percentage being 42.10%. Blackrock Inc. is the largest shareholder of the company, while 122 institutions own stock in it. As of Mar 30, 2022, the company held over 2.5 million shares (or 5.76% of all shares), a total value of $6.19 million in shares.
The next largest institutional holding, with 1.91 million shares, is of Vanguard Group, Inc. (The)’s that is approximately 4.42% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $4.75 million.
Also, the Mutual Funds coming in first place with the largest holdings of Cardiff Oncology Inc. (CRDF) shares are Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund and Vanguard Total Stock Market Index Fund. Data provided on Mar 30, 2022 indicates that Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund owns about 1.47 million shares. This amounts to just over 3.39 percent of the company’s overall shares, with a $3.64 million market value. The same data shows that the other fund manager holds slightly less at 1.14 million, or about 2.63% of the stock, which is worth about $2.82 million.